EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma

Annals of Oncology

Volumn 26, Issue 6, 2015, Pages 1118-1123

  Davis, Ian D ^a,b   Long, A ^b,c   Yip, S ^b,c   Espinoza, D ^b,c   Thompson, J F ^b,c   Kichenadasse, G ^b,d   Harrison, M ^b,e,f   Lowenthal, R M ^b,g   Pavlakis, N ^b,c   Azad, A ^b,h   Kannourakis, G ^b,i,j   Steer, C ^b,k   Goldstein, D ^b,l   Shapiro, J ^b,m   Harvie, R ^b,n   Jovanovic, L ^o   Hudson, A L ⁿ   Nelson, C C ^b,o   Stockler, M R ^b,c,e,p   Martin, A ^b,c  

^a MONASH UNIVERSITY   (Australia)

^b ANZUP Cancer Trials Groups   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f LIVERPOOL HOSPITAL   (Australia)

^g UNIVERSITY OF TASMANIA   (Australia)

^h AUSTIN HEALTH   (Australia)

ⁱ Fiona Elsey Cancer Research Institute   (Australia)

^j UNIVERSITY OF BALLARAT   (Australia)

^k Border Medical Oncology Australia   (Australia)

^l UNIVERSITY OF NEW SOUTH WALES   (Australia)

^m CABRINI HOSPITAL   (Australia)

ⁿ UNIVERSITY OF SYDNEY   (Australia)

^o QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^p Department of Medical Oncology   (Australia)

more..

Author keywords

Angiogenesis inhibitors; Clinical trial; Everolimus; Renal cell carcinoma; Sunitinib; Vascular endothelial growth factor receptors

Indexed keywords

ANTIHYPERTENSIVE AGENT; EVEROLIMUS; GAMMA GLUTAMYLTRANSFERASE; SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN RECEPTOR;

ADULT; ANEMIA; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEMALE; HEART FAILURE; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; ORAL MUCOSITIS; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SEPSIS; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR GROWTH; AGED; ANTAGONISTS AND INHIBITORS; AUSTRALIA; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; ENZYMOLOGY; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EVEROLIMUS; FEASIBILITY STUDIES; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RISK FACTORS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84938082769     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv078     Document Type: Article

References (11)

1. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
2. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
3. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
4. Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus sorafenib as secondline treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013; 14:552-562.
5. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
6. Buczek M, Escudier B, Bartnik E et al. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. Biochim Biophys Acta 2014; 1845: 31-41.
7. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
8. Motzer RJ, Barrios CH, Kim TM et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32: 2765-2772.
9. Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New Engl J Med 2013; 369: 722-731.
10. Zama IN, Hutson TE, Elson P et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010; 116: 5400-5406.
11. Pal SK, Hu A, Chang M, Figlin RA. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions. Clin Adv Hematol Oncol 2014; 12:90-99.